{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:09:46Z","timestamp":1790636986331,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.amjcard.2017.06.015","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T15:15:55Z","timestamp":1498662955000},"page":"893-897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Comparison of Low-Dose Statin Versus Low-Dose Statin\u2009+\u2009Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial)"],"prefix":"10.1016","volume":"120","author":[{"given":"Giuseppe","family":"Marazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Campolongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pelliccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Quattrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cacciotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Volterrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2017.06.015_bib0010","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0015","doi-asserted-by":"crossref","first-page":"f880","DOI":"10.1136\/bmj.f880","article-title":"Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases","volume":"346","author":"Dormuth","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0020","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/MAJ.0b013e31825b8edf","article-title":"Incidence of musculoskeletal and neoplastic diseases in patients on statin therapy: results of a retrospective cohort analysis","volume":"345","author":"Mansi","year":"2013","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0025","doi-asserted-by":"crossref","first-page":"g3244","DOI":"10.1136\/bmj.g3244","article-title":"Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases","volume":"348","author":"Dormuth","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0030","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.numecd.2012.04.012","article-title":"Discontinuation of statin therapy due to muscular side effects: a survey in real life","volume":"23","author":"Rosenbaum","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0040","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ejim.2011.04.007","article-title":"Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic","volume":"22","author":"Pirro","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0045","first-page":"121","article-title":"Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome","volume":"7","author":"Cicero","year":"2009","journal-title":"Curr Top Nutraceutical Res"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1476-511X-11-123","article-title":"Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment","volume":"11","author":"Pisciotta","year":"2012","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.003","article-title":"A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: review of the clinical evidence","volume":"24","author":"Barrios","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0060","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.phrs.2016.04.021","article-title":"The effects of a nutraceutical combination on plasma lipids and glucose: a systematic review and meta-analysis of randomized controlled trials","volume":"110","author":"Pirro","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0065","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0070","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.amjcard.2015.09.023","article-title":"Usefulness of nutraceuticals (Armolipid plus) versus ezetimibe and combination in statin-intolerant patients with dyslipidemia with coronary heart disease","volume":"116","author":"Marazzi","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0075","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2710.2009.01085.x","article-title":"A systematic review and meta-analysis on the therapeutic equivalence of statins","volume":"35","author":"Weng","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0080","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0085","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF01745510","article-title":"Chemistry, biochemistry, and pharmacology of HMG-CoA reductase inhibitors","volume":"66","author":"Endo","year":"1988","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0188-4409(00)00265-4","article-title":"Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts","volume":"32","author":"Menendez","year":"2001","journal-title":"Arch Med Res"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0095","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.atherosclerosis.2008.02.004","article-title":"Berberine decreases PCSK9 expression in HepG2 cells","volume":"201","author":"Cameron","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0100","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm1135","article-title":"Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins","volume":"10","author":"Kong","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0105","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.nutres.2016.07.005","article-title":"Low daily dose of 3\u2009mg monacolin K from RYR reduces the concentration of LDL-C in a randomiized, placebo-controlled intervention","volume":"36","author":"Heinz","year":"2016","journal-title":"Nutr Res"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0110","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2165\/00044011-200525110-00003","article-title":"Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients","volume":"25","author":"Reiner","year":"2005","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0115","doi-asserted-by":"crossref","first-page":"553","DOI":"10.2217\/clp.09.41","article-title":"Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results","volume":"4","author":"Cicero","year":"2009","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0120","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jep.2014.09.049","article-title":"Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension","volume":"161","author":"Lan","year":"2015","journal-title":"J Ethnopharmacol"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0125","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.atherosclerosis.2015.04.004","article-title":"Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain\u2014a systematic review and meta-analysis","volume":"240","author":"Gerards","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0130","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/bcp.13171","article-title":"Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system","volume":"83","author":"Mazzanti","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0135","first-page":"2304","article-title":"Scientific opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL-cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924\/2006","volume":"9","author":"EFSA, Panel of Dietetic Products","year":"2011","journal-title":"EFSA J"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0140","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1074\/jbc.M708098200","article-title":"The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2","volume":"283","author":"Poirier","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0145","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","article-title":"Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial","volume":"129","author":"Koren","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0150","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1161\/CIRCULATIONAHA.116.024604","article-title":"Reductions in atherogenic lipids and major cardiovascular events. A pooled analysis of 10 ODYSSEY trials comparing alirocumab with control","volume":"134","author":"Ray","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.06.015_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance\u2014an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch Med Sci"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917310238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917310238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:28:03Z","timestamp":1757572083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914917310238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0002914917310238"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.06.015","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Low-Dose Statin Versus Low-Dose Statin\u2009+\u2009Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial)","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}